Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longzhu Ointment (龙珠软膏) is a traditional Chinese medicine (TCM) topical formulation developed and manufactured by Ma Yinglong Pharmaceutical Group. It is primarily indicated for the treatment of various inflammatory skin and anorectal conditions, including hemorrhoids, boils, furuncles, and minor burns. The ointment's formulation is a complex mixture of ingredients such as artificial musk, artificial bezoar, pearl, amber, borax, borneol, and calamine, which work synergistically according to TCM principles to clear heat, detoxify, reduce swelling and pain, and promote tissue regeneration. As a traditional formulation, it lacks a specific molecular target but is widely utilized in China for symptomatic relief of perianal and dermatological disorders. It is classified as an OTC Class B medication and is included in China's National Medical Insurance Directory.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longzhu Ointment.